Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients

17Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Mold-active azole antifungals are commonly prescribed for the prevention of invasive fungal infections in lung transplant recipients. Each agent exhibits a unique pharmacologic profile, an understanding of which is crucial for therapy selection and optimization. This article reviews pharmacologic considerations for three frequently-used azole antifungals in lung transplant recipients: voriconazole, posaconazole, and isavuconazole. Focus is drawn to analysis of drug-interactions, adverse drug reactions, pharmacokinetic considerations, and the role of therapeutic drug monitoring with special emphasis on data from the post-lung transplant population.

Cite

CITATION STYLE

APA

Klatt, M. E., & Eschenauer, G. A. (2021). Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. Journal of Fungi, 7(2), 1–16. https://doi.org/10.3390/jof7020076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free